Cannabis Law Report

AUGUST 17, 2021

–(BUSINESS WIRE)– $MRNS #MarinusPharma — Marinus Pharmaceuticals, Inc. Ganaxolone was generally well-tolerated with somnolence reported as the most common adverse event, consistent with previous trials; in addition, one treatment-related serious adverse event of seizure was reported in the trial. RADNOR, Pa.–(BUSINESS

Pharmaceutical 98

Pharmaceutical Clinical Trials Treatment Patients 98

NORML

MAY 26, 2020

The delivery of precise doses of THC via an inhaler is associated with pain mitigation in patients with neuropathy and other complex pain conditions, according to clinical trial data published in the European Journal of Pain. Adverse events were mostly mild and resolved spontaneously.

Clinical Trials 239

Clinical Trials Chronic Pain Cannabinoids Patients 239

Cannabis Law Report

JANUARY 4, 2022

AUSTIN, Texas–(BUSINESS WIRE)–Anebulo Pharmaceuticals, Inc. About Anebulo Pharmaceuticals, Inc. Anebulo Pharmaceuticals, Inc. Except as required by federal securities law, Anebulo Pharmaceuticals undertakes no obligation to update or revise forward-looking statements to reflect changed conditions.

Pharmaceutical 52

Pharmaceutical Research and Development Clinical Trials Cannabinoids 52

Cannabis Law Report

NOVEMBER 12, 2021

AUSTIN, Texas–(BUSINESS WIRE)– Anebulo Pharmaceuticals, Inc. In compliance with current Good Manufacturing Practice requirements, the Company delivered ANEB-001’s active pharmaceutical ingredient to its contract manufacturer to fill into 10 mg and 50 mg capsules for finished product. About Anebulo Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Business Research and Development 52

Cannabis Law Report

SEPTEMBER 22, 2021

Under the terms of the agreement OCT will use reasonable efforts to develop and commercialise: (i) at least one CBD derivative; (ii) at least one CBG derivative; and (iii) at least one THC derivative, as pharmaceutical drug products. The principal objective of Programme 3 is to identify a drug candidate(s) for neuropathic pain conditions.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Cannabinoids 52

Puff Puff Post

MARCH 10, 2020

SOURCE InMed Pharmaceuticals Inc. About InMed: InMed Pharmaceuticals is a clinical stage pharmaceutical company developing a pipeline of cannabinoid-based medications, initially focused on the therapeutic benefits of cannabinol (CBN) in diseases with high unmet medical need.

Clinical Trials 84

Clinical Trials Pharmaceutical Research and Development Cannabinoids 84

Cannabis Law Report

JANUARY 3, 2022

AUSTIN, Texas–(BUSINESS WIRE)– Anebulo Pharmaceuticals, Inc. About Anebulo Pharmaceuticals, Inc. Anebulo Pharmaceuticals, Inc. Except as required by federal securities law, Anebulo Pharmaceuticals undertakes no obligation to update or revise forward-looking statements to reflect changed conditions.

Pharmaceutical 52

Pharmaceutical Cannabinoids Treatment Clinical Trials 52

Cannabis Law Report

DECEMBER 1, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, today announced that it will participate in two investor conferences during the month of December 2021. MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Chronic Pain Therapy 52

Cannabis Law Report

SEPTEMBER 24, 2019

Here is the BBC report and below you will find the full press release from GW Pharmaceuticals. Epidyolex has been approved as a treatment option for children as young as two with Lennox-Gastaut syndrome or Dravet syndrome – difficult-to-treat conditions that can cause multiple seizures a day. ” Source BBC: [link].

Pharmaceutical 55

Pharmaceutical Epilepsy Research and Development Medicine 55

Cannabis Law Report

DECEMBER 3, 2021

–(BUSINESS WIRE)– $MRNS #MarinusPharma — Marinus Pharmaceuticals, Inc. Chief Executive Officer of Marinus Pharmaceuticals. “We Ganaxolone was generally well-tolerated with somnolence reported as the most common adverse event, consistent with previous trials. About Marinus Pharmaceuticals. ET (12:00 p.m.

Epilepsy 52

Epilepsy Pharmaceutical Data Clinical Trials 52

Cannabis Law Report

OCTOBER 5, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced that it will present at the Benzinga Rising Stars: Catalytic Small Cap Growth Conference on Thursday, October 7, 2021. 646) 421-9523.

Pharmaceutical 52

Pharmaceutical Clinical Trials Chronic Pain Media 52

Cannabis Law Report

SEPTEMBER 22, 2021

New data will be presented at the 4th Annual International Cannabinoid-Derived Pharmaceuticals Summit in Boston. BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. We believe that the new data we are revealing today is an extraordinary achievement in the field of pharmaceutical cannabinoids,” said Adam Kaplin, M.D.,

Pharmaceutical 52

Pharmaceutical Data CBD Clinical Trials 52

Cannabis Law Report

NOVEMBER 18, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical-stage pharmaceutical company committed to extending healthy lifespan, announced today that its investment company Oravax Medical Inc. Oravax”), partially owned with its majority partner Oramed Pharmaceuticals Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Business Chronic Pain 52

Cannabis Law Report

OCTOBER 26, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, announced today that Chris Chapman, M.D., Chapman has operated Chapman Pharmaceutical Consulting, Inc., About MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

JANUARY 5, 2022

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, announced that the U.S. About MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals, Inc. 2 Goates et al. 4 [link].

Pharmaceutical 52

Pharmaceutical Clinical Trials Therapy Treatment 52

Cannabis Law Report

NOVEMBER 23, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, announced that the U.S. About MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals, Inc. MyMD Contact: Robert Schatz.

Pharmaceutical 52

Pharmaceutical Clinical Trials Therapy Chronic Pain 52

Cannabis Law Report

NOVEMBER 16, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, announced today that it has received U.S. About MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals, Inc. 646) 421-9523.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

SEPTEMBER 13, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced that it intends to initiate dosing for a Phase 2 trial of MYMD-1’s function in delaying aging early in the fourth quarter of 2021.

Clinical Trials 52

Clinical Trials Pharmaceutical Research and Development Therapy 52

Cannabis Law Report

DECEMBER 29, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical-stage pharmaceutical company committed to extending healthy lifespan, announced today that its investment company Oravax Medical Inc. Oravax”), partially owned with its majority partner Oramed Pharmaceuticals Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Chronic Pain CBD 52

Cannabis Law Report

OCTOBER 19, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, announced today that it will present at the Dawson James Securities 6th Annual Small Cap Growth Conference on Thursday, October 21, 2021, at 4:30 p.m.

Pharmaceutical 52

Pharmaceutical Therapy Clinical Trials Chronic Pain 52

CannaMD

FEBRUARY 19, 2020

Post-traumatic stress disorder (PTSD) is a condition most often associated with military veterans, but it is not confined to wartime experiences. Medical Marijuana: More Effective Than Pharmaceuticals? To date, there is no pharmaceutical product targeted specifically for the treatment of PTSD.

CBD 92

CBD Pharmaceutical Research and Development Conditions 92

Cannabis Law Report

JANUARY 4, 2022

With the conditional approval, ADCL can immediately employ the Linea 2.0 With the conditional approval, ADCL can immediately employ the Linea 2.0 Hayward, president and CEO of Applied DNA, stated, “We are grateful to the NYSDOH for conditional approval of our Linea 2.0 Assay (the “Linea 2.0 The Linea 2.0 Dr. James A.

Conditions 52

Conditions Research and Development Therapy Supply Chain 52

Puff Puff Post

MARCH 10, 2020

SOURCE InMed Pharmaceuticals Inc. About InMed: InMed Pharmaceuticals is a clinical stage pharmaceutical company developing a pipeline of cannabinoid-based medications, initially focused on the therapeutic benefits of cannabinol (CBN) in diseases with high unmet medical need.

Clinical Trials 40

Clinical Trials Pharmaceutical Research and Development Cannabinoids 40

Cannabis Law Report

JUNE 28, 2021

Pharmaceutical and Medical Cannabis Leaders Zambon GmbH and Adven GmbH will Drive Medical Cannabis Supporting Treatments for Neurological Therapies. Zambon is a multinational pharmaceutical company that focuses on innovation and development with the aim to improve patients’ lives. The market for medical cannabis in Germany.

Access 105

Access Research and Development Pharmaceutical Therapy 105

FloridaMarijuana.net

AUGUST 15, 2018

Evidence-based Complementary and Alternative Medicine published an article titled “Post-Traumatic Stress Disorder: Evidence-Based Research for the Third Millennium” which describes how profound the symptoms of PTSD can be: “Traumatic events are profoundly stressful. Women tend to experience different traumas than men.

Treatment 182

Treatment Marijuana Research and Development Therapy 182

Cannabis Law Report

JULY 19, 2021

Philip Morris International recently offered £1 billion to buy Vectura Group PLC, the British pharmaceutical company that develops inhaled medical products. The global market for inhalation drug delivery devices is predicted to reach $17.6 billion by 2027. About RYAH Group, Inc.

Therapy 76

Therapy Data Research and Development Events 76

Cannabis Law Report

AUGUST 25, 2021

The purchase and amalgamation of Consolidated Craft Brands was announced on March 19, 2021 bringing CPG and pharmaceutical manufacturing experience and Health Canada licenses for R&D. Actual results and future events could differ materially from those anticipated in such forward-looking statements. www.rapid-dose.com.

Events 111

Events Pharmaceutical Research and Development Business 111

Veriheal

JULY 12, 2021

According to the American Psychiatric Association , PTSD is a “psychiatric disorder that may occur in people who have experienced or witnessed a traumatic event such as natural disaster, as a serious accident, a terrorist act, war/combat or rape or who have been threatened with death, sexual violence or serious injury”.

Treatment 104

Treatment Sleep Clinical Trials Data 104

Cannabis Law Report

NOVEMBER 23, 2019

for the production R&D of pharmaceutical grade standardised cannabis. Here the company shares their evolution with Health Europa, exploring the production of pharmaceutical grade standardised cannabis. KANNABEIRA® is a project and a registered trademark under the company Green Donation, Ltd. KANNABEIRA and standardised cannabis.

Pharmaceutical 45

Pharmaceutical Research and Development Cultivation Environment 45

Cannabis Law Report

OCTOBER 15, 2021

The ongoing research targets the treatment of respiratory disorders in support of a pharmaceutical being developed by PAOG under the name RespRx. PAOG’s RespRx research has shown effectiveness in the treatment of Chronic Obstructive Pulmonary Disease (COPD) and other similar respiratory conditions.

Treatment 52

Treatment Research and Development CBD eCommerce 52

Cannabis Law Report

JUNE 16, 2021

“Santé is a key partner to for Wake as they are a leading contract research organization (CRO) in Canada with expertise in advancing plant-based pharmaceutical products through various phases of clinical trial development.

Clinical Trials 104

Clinical Trials Therapy Research and Development Events 104

Cannabis Law Report

OCTOBER 6, 2021

Flora Pharma will seek to identify scientific gaps in the cannabis industry and ultimately work to translate that to pharmaceutical cannabis products backed by data. MIAMI & TORONTO–(BUSINESS WIRE)–Flora Growth Corp.

Clinical Trials 52

Clinical Trials Research and Development Pharmaceutical Events 52

Cannabis Law Report

JUNE 16, 2021

The platform was specifically designed to power the traceability of testing standards within the legal cannabis, nutraceutical, food and pharmaceutical space with a focus on the authentication of source materials or ingredients used in formulation. For more information, please visit www.trutrace.co.

Events 74

Events Access Legislation Conditions 74

Cannabis Law Report

JANUARY 12, 2022

“This is a landmark event for Gb Sciences,” said Chairman and CEO John Poss. and 43 international patent-pending applications, which provide patent protection for both PhAROS™, its proprietary drug discovery engine, and its novel, plant-inspired combination drugs for the treatment of more than 65 serious medical conditions.

Research and Development 52

Research and Development Clinical Trials Chronic Pain Therapy 52

CannaTech

APRIL 1, 2020

When I was at Pharmacy School at Sydney University, more than 20 years ago, we learned the pharmaceutical and clinical sciences ranging from the design, synthesis, formulation, dispensing and testing of drugs and the clinical and social aspects of pharmacy. And most especially in these times, cannabis is used effectively to treat anxiety.

Supply Chain 98

Supply Chain Chronic Pain Pharmaceutical Patients 98

Cannabis Law Report

JUNE 23, 2021

The data collection is relevant for clinics, doctors, dispensaries and pharmaceutical companies and licensed processors (LPs) to monitor and manage formulation effects on patients and demographics. With a strong IP portfolio, RYAH gathers deep and insightful data on the complete patient session and formulation life cycle.

Programs 100

Programs Data Events Collective 100

NORML

JANUARY 24, 2019

The bill would also allow Virginia’s licensed pharmaceutical processors to dispense medical cannabis preparations beyond the current definition of “oil” and in doses proven effective for the variety of disease processes for which doctors will recommend these therapies.

Policy 152

Policy Patients Education Legislation 152